Annovis Bio Inc (ANVS) is a Healthcare · Biotechnology company listed on NYSE. Price $1.15 (+4.55%), Market cap $0.07B, 52-week low–high $1.59 ~ $5.10.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Financial statements, price targets, institutional (13F) holdings and related news for Annovis Bio Inc are updated in real time on BlackAll Trade.
Annovis Bio Inc trades at $1.15 (+4.55%). Real-time quotes and charts are available on BlackAll Trade.
Annovis Bio Inc has a market cap of about $0.07B.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to tr